76935-76-7

Usage

Uses

Used in Pharmaceutical Research:
3-Ethoxyphenethylamine is used as a research compound for studying its potential psychoactive properties and effects. Its structural similarity to other known psychoactive substances makes it a valuable candidate for understanding the mechanisms of action and potential therapeutic applications in the field of psychopharmacology.
Used in Drug Development:
Due to its psychoactive nature, 3-ethoxyphenethylamine may be utilized in the development of new drugs targeting specific neurological conditions or disorders. Further research is required to explore its potential benefits and risks, as well as to determine its efficacy and safety profile.
Used in Forensic Toxicology:
3-Ethoxyphenethylamine may also be used in forensic toxicology for the identification and analysis of psychoactive substances in biological samples. Its unique chemical structure can aid in the detection and differentiation of various phenethylamines in cases of drug abuse or intoxication.

InChI:InChI=1/C10H15NO/c1-2-12-10-5-3-4-9(8-10)6-7-11/h3-5,8H,2,6-7,11H2,1H3

Upstream product

• 3159-51-1 1-ethoxy-3-(2-nitro-ethyl)-benzene 

Downstream Products

• 149488-31-3 N-[2-(3-ethoxyphenyl)ethyl]-N'-(2-thiazolyl)thiourea 
• 1372808-79-1 4-(aminosulfonyl)-N-[2-(3-ethoxyphenyl)ethyl]benzamide 
• 21581-46-4 (3-ethoxy-phenethyl)-methyl-amine 
• 630407-52-2 6-ethoxy-1,2,3,4-tetrahydro-isoquinoline 

Relevant academic research and scientific papers

Method for inhibition of HIV related viruses

Treatment of AIDS, inhibition of the replication of HIV and related viruses thereof, and formulations using thiourea derivative compounds or salts thereof is disclosed. Also disclosed are novel thiourea derivative compounds.

Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs

A novel series of potent specific HIV-1 inhibitory compounds is described. The lead compound in the series, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (1), inhibits HIV-1 RT using rCdG as the template with an IC50 of 0.9 μM. In MT-4 cells, compound 1 inhibits HIV-1 with an ED50 of 1.3 μM. The 50% cytotoxic dose in cell culture is >380 μM. The chemical structure-activity relationship (SAR) was developed by notionally dividing the lead compound in four quadrants. The SAR strategy had two phases. The first phase involved optimization of antiviral activity through independent variation of quadrants 1-4. The second phase involved the preparation of hybrid structures combining the best of these substituents. Further SAR studies and pharmacokinetic considerations led to the identification of N-(2-pyridyl)-N'-(5-bromo-2- pyridyl)-thiourea (62; LY300046 · HCl) as a candidate for clinical evaluation. LY300046 · HCl inhibits HIV-1 RT with an IC50 of 15 nM and in cell culture has an ED50 of 20 nM.

Process for the preparation of (8As,12AS,13AS)-decahydroisoquino ((2,1-G) (1,6)-naphthyridin-8-one derivatives

The invention provides a process for preparing single enantiomers of compounds represented by the formula: STR1 and chiral acid addition salts thereof; wherein: X and Y are independently hydrogen; lower alkyl; lower alkoxy; or halo; or X and Y taken together is methylenedioxy or ethylene-1,2-dioxy; which includes reduction of a compound represented by the formula: STR2 to give a mixture of stereoisomers represented by the formula: STR3 wherein each wavy line independently represents a bond in either the α or β position; followed by dissolving the mixture of stereoisomers and a chiral resolving acid in a suitable solvent and allowing the solution to crystallize, giving a salt of the desired enantiomer.